Structure Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on February 26, 2026.
| | |
|---|---|
| STRUCTURE THERAPEUTICS INC. | |
| By: | /s/ Raymond Stevens, Ph.D. |
| | Raymond Stevens, Ph.D.Chief Executive Officer |
| | |
| By: | /s/ Jun Yoon |
| | Jun YoonChief Financial Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Raymond Stevens and Jun Yoon, jointly and severally, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
| SIGNATURE | | TITLE | | DATE |
|---|---|---|---|---|
| | | | | |
| /s/ Raymond Stevens, Ph.D. | | Chief Executive Officer and Director | | February 26, 2026 |
| Raymond Stevens, Ph.D. | | (Principal Executive Officer) | | |
| | | | | |
| /s/ Jun Yoon | | Chief Financial Officer and Director | | February 26, 2026 |
| Jun Yoon | | (Principal Financial and Accounting Officer) | | |
| | | | | |
| /s/ Daniel Welch | | Chairman | | February 26, 2026 |
| Daniel Welch | | | ||
| | | | | |
| /s/ Eric Dobmeier | | Director | | February 26, 2026 |
| Eric Dobmeier | | | ||
| | | | | |
| /s/ Ted W. Love, M.D. | | Director | | February 26, 2026 |
| Ted W. Love, M.D. | | | ||
| | | | | |
| /s/ Angus Russell | | Director | | February 26, 2026 |
| Angus Russell | | | ||
| | | | | |
| /s/ Sharon Tetlow | | Director | | February 26, 2026 |
| Sharon Tetlow | | | ||
| | | | | |
| /s/ Joanne Waldstreicher, M.D. | | Director | | February 26, 2026 |
| Joanne Waldstreicher, M.D. | | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.